Orexo AB (publ) ORXOY
0.44 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.4429 Day range 0.443
0.4429 52-week range 3.00
- YTD
- -82.96%
- 1 year
- -85.18%
News
seekingalpha.com Orexo AB (publ) (ORXOY) Q3 2026 Earnings Call Transcript Orexo AB (publ) (ORXOY) Q3 2026 Earnings Call Transcript
prnewswire.com Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice /PRNewswire/ -- Orexo AB (publ) (STO: ORX) (OTCQX: ORXOY) today announced that the company has reached a non-binding agreement in principle on the main
prnewswire.com Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice /PRNewswire/ -- Orexo AB (publ) (STO: ORX) (OTCQX: ORXOY) today announced that the company has reached a non-binding agreement in principle on the main
seekingalpha.com Orexo AB (publ) (ORXOY) Q2 2026 Earnings Call Transcript Orexo AB (publ) (ORXOY) Q2 2026 Earnings Call Transcript
seekingalpha.com Orexo AB (publ) (ORXOY) Q1 2026 Earnings Call Transcript Orexo AB (publ) (ORXOY) Q1 2026 Earnings Call Transcript
prnewswire.com Invitation & Agenda: Orexo R&D Day on March 24 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The- prnewswire.com Invitation & Agenda: Orexo R&D Day on March 24 UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026.
prnewswire.com Orexo changes the organizational structure and management team to increase focus on development of new products UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team.
seekingalpha.com Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript
seekingalpha.com Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript
seekingalpha.com Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript Orexo AB (publ) (OTCQX:ORXOY) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Nikolaj Sørensen - President & CEO Frederik Jarrsten - Executive VP & CFO Edward Kim Conference…
prnewswire.com Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared…
prnewswire.com Orexo to present clinical data for OX640 at the EAACI Congress OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technology EAACI is a…
prnewswire.com Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields. Both formulations…
prnewswire.com Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.
prnewswire.com Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical…
prnewswire.com Orexo initiates new study of OX640 in participants with allergic rhinitis OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.
prnewswire.com Orexo´s Nomination Committee for the Annual General Meeting 2025 UPPSALA, Sweden , Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises of the…
prnewswire.com Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024 UPPSALA, Sweden , Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.
prnewswire.com Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food and Drug…